BRIDGEWATER, N.J., Nov. 1, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:
- The Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 8, 2022, at 2:35 PM ET in a fireside chat
- The Stifel 2022 Healthcare Conference in New York, NY, on Tuesday, November 15, 2022, at 2:25 PM ET in a fireside chat
- The Evercore ISI 5th Annual HealthCONx Virtual Conference on Wednesday, November 30, 2022, at 8:50 AM ET in a fireside chat
Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
SOURCE Insmed Incorporated
